dolastatin 10
Recently Published Documents


TOTAL DOCUMENTS

96
(FIVE YEARS 6)

H-INDEX

30
(FIVE YEARS 2)

Author(s):  
Hodaya Gutman ◽  
Andrii Bazylevich ◽  
Chandrashekhar Prasad ◽  
Ortal Dorfman ◽  
Arkadi Hesin ◽  
...  

Marine Drugs ◽  
2021 ◽  
Vol 19 (7) ◽  
pp. 363
Author(s):  
Gang Gao ◽  
Yanbing Wang ◽  
Huiming Hua ◽  
Dahong Li ◽  
Chunlan Tang

Dolastatin 10 (Dol-10), a leading marine pentapeptide isolated from the Indian Ocean mollusk Dolabella auricularia, contains three unique amino acid residues. Dol-10 can effectively induce apoptosis of lung cancer cells and other tumor cells at nanomolar concentration, and it has been developed into commercial drugs for treating some specific lymphomas, so it has received wide attention in recent years. In vitro experiments showed that Dol-10 and its derivatives were highly lethal to common tumor cells, such as L1210 leukemia cells (IC50 = 0.03 nM), small cell lung cancer NCI-H69 cells (IC50 = 0.059 nM), and human prostate cancer DU-145 cells (IC50 = 0.5 nM), etc. With the rise of antibody-drug conjugates (ADCs), milestone progress was made in clinical research based on Dol-10. A variety of ADCs constructed by combining MMAE or MMAF (Dol-10 derivatives) with a specific antibody not only ensured the antitumor activity of the drugs themself but also improved their tumor targeting and reduced the systemic toxicity. They are currently undergoing clinical trials or have been approved for marketing, such as Adcetris®, which had been approved for the treatment of anaplastic large T-cell systemic malignant lymphoma and Hodgkin lymphoma. Dol-10, as one of the most medically valuable natural compounds discovered up to now, has brought unprecedented hope for tumor treatment. It is particularly noteworthy that, by modifying the chemical structure of Dol-10 and combining with the application of ADCs technology, Dol-10 as a new drug candidate still has great potential for development. In this review, the biological activity and chemical work of Dol-10 in the advance of antitumor drugs in the last 35 years will be summarized, which will provide the support for pharmaceutical researchers interested in leading exploration of antitumor marine peptides.


2020 ◽  
Author(s):  
Keyword(s):  

2020 ◽  
Vol 7 (1) ◽  
pp. 76-103
Author(s):  
Xiao-Di Nie ◽  
Zhuo-Ya Mao ◽  
Wen Zhou ◽  
Chang-Mei Si ◽  
Bang-Guo Wei ◽  
...  

A diastereoselective approach to obtain amino alcohols through SmI2-induced radical addition and divergent synthesis of dolastatin 10 are described.


Marine Drugs ◽  
2019 ◽  
Vol 17 (6) ◽  
pp. 320 ◽  
Author(s):  
Justine Demay ◽  
Cécile Bernard ◽  
Anita Reinhardt ◽  
Benjamin Marie

Cyanobacteria are photosynthetic microorganisms that colonize diverse environments worldwide, ranging from ocean to freshwaters, soils, and extreme environments. Their adaptation capacities and the diversity of natural products that they synthesize, support cyanobacterial success in colonization of their respective ecological niches. Although cyanobacteria are well-known for their toxin production and their relative deleterious consequences, they also produce a large variety of molecules that exhibit beneficial properties with high potential in various fields (e.g., a synthetic analog of dolastatin 10 is used against Hodgkin’s lymphoma). The present review focuses on the beneficial activities of cyanobacterial molecules described so far. Based on an analysis of 670 papers, it appears that more than 90 genera of cyanobacteria have been observed to produce compounds with potentially beneficial activities in which most of them belong to the orders Oscillatoriales, Nostocales, Chroococcales, and Synechococcales. The rest of the cyanobacterial orders (i.e., Pleurocapsales, Chroococcidiopsales, and Gloeobacterales) remain poorly explored in terms of their molecular diversity and relative bioactivity. The diverse cyanobacterial metabolites possessing beneficial bioactivities belong to 10 different chemical classes (alkaloids, depsipeptides, lipopeptides, macrolides/lactones, peptides, terpenes, polysaccharides, lipids, polyketides, and others) that exhibit 14 major kinds of bioactivity. However, no direct relationship between the chemical class and the respective bioactivity of these molecules has been demonstrated. We further selected and specifically described 47 molecule families according to their respective bioactivities and their potential uses in pharmacology, cosmetology, agriculture, or other specific fields of interest. With this up-to-date review, we attempt to present new perspectives for the rational discovery of novel cyanobacterial metabolites with beneficial bioactivity.


2019 ◽  
Vol 17 (35) ◽  
pp. 8115-8124 ◽  
Author(s):  
Kanwen Yang ◽  
Bo Chen ◽  
Diego A. Gianolio ◽  
James E. Stefano ◽  
Michelle Busch ◽  
...  

A cytotoxic reagent-free fragment coupling methodology was developed to produce hydrophilic drug linkers to prepare aggregation free antibody–drug conjugates.


ACS Omega ◽  
2018 ◽  
Vol 3 (5) ◽  
pp. 5212-5221 ◽  
Author(s):  
Michinori Akaiwa ◽  
Tioga Martin ◽  
Brian A. Mendelsohn

2018 ◽  
Vol 26 (8) ◽  
pp. 1643-1652 ◽  
Author(s):  
Shinya Yokosaka ◽  
Akiko Izawa ◽  
Chizuka Sakai ◽  
Eri Sakurada ◽  
Yasuhiro Morita ◽  
...  
Keyword(s):  

2017 ◽  
Vol 80 (9) ◽  
pp. 2484-2491 ◽  
Author(s):  
Julien Dugal-Tessier ◽  
Stuart D. Barnscher ◽  
Akira Kanai ◽  
Brian A. Mendelsohn

Tetrahedron ◽  
2017 ◽  
Vol 73 (16) ◽  
pp. 2255-2266 ◽  
Author(s):  
Xin Wang ◽  
Suzhen Dong ◽  
Dengke Feng ◽  
Yazhou Chen ◽  
Mingliang Ma ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document